Board of Directors

We are fortunate that the Board of Sphere Medical has such a depth and breadth of commercial and industry specific expertise. The Board determines the strategic direction of the company and charts its future course.

Dr David Martyr, Non-Executive Chairman

Dr Martyr has held several senior level positions of medical, diagnostic, life science and laser technology companies for more than 20 years.  He is currently CEO of Tecan AG, a Swiss listed laboratory instruments and solutions company with a market capitalisation of over CHF1BN.  Prior to that he spent 13 years at Leica Microsystems which was acquired by Danaher Corporation in 2005, his last position being Group President Leica Microsystems with US$1.3BN of sales and 4,500 employees and simultaneously VP & Group Executive, Danaher Corporation, with responsibility for the development of the Life Science and Diagnostics business platform.  David is also a Non-Executive Director of ALDA (Analytical Life Science Diagnostics Association), based near Washington DC.

Luciën van Os, CEO, Director

large_Lucien van Os 2016.jpg

Luciën van Os has more than 12 years’ experience in the medical device industry, having worked for companies such as Medtronic and Gambro in senior management positions as well as being CEO of small and mid-sized companies. He has an engineering background and has also worked for more than 15 years in various engineering and R&D roles for companies such as Philips and Ericsson.  Luciën has significant experience in bringing new technologies and products to market such as DECT cordless products, Bluetooth accessories, fully digital pacemakers, remote monitoring of cardiac pacemaker patients and injectable cardiac monitoring devices.

Richard Wright, CFO, Director

Mr Wright joined the Board in August 2015.  He is a Chartered Accountant with more than 20 years of experience in financial roles across a variety of sectors. Prior to joining Sphere Medical, he was Finance Director of Alliance Pharma plc, the UK based AIM-listed speciality pharmaceutical company for eight years.  Richard has also previously held senior finance positions at FirstGroup plc, Somerfield plc and Parragon Books Limited.  Richard read Mathematics at the University of Cambridge and qualified as an accountant with Ernst & Young LLP.

Stephen H Mahle, Non-Executive Director

Mr Mahle is the former Executive Vice President of Medtronic Inc., one of the world's largest medical device companies. He held numerous senior leadership positions with the company, including leading Medtronic's largest division as President of the Pacing Business and subsequently as President of Cardiac Rhythm Disease Management, which had sales of US$4.5BN and 12,000 employees. He retired in 2009 after 37 years. Prior to joining Medtronic, Stephen was a Captain in the US Army where he served as a research scientist at the NASA Manned Spacecraft Center in Houston. Stephen currently serves on the board of EBR Inc., an implantable medical device start-up based in Sunnyvale CA.  He holds a Bachelor of Science degree in physics from Beloit College and a Masters degree in physics from Pennsylvania State University.

Meinhard Schmidt, Non-Executive Director

Mr Schmidt has more than 20 years of international experience as an entrepreneur and senior executive in the healthcare, diagnostics and medical devices industries. Between 1998 and 2008 Meinhard was at Roche Diagnostics where he held various senior leadership roles in Diabetes Care, Lab Diagnostics and was Senior VP and Head of Roche Decentralized Solutions, which achieved the leading global position in the Near Patient Testing market. Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, programme and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. Meinhard is currently a Board Director at valuationLAB AG and CeQur AG, and Chairman at Promimic AB and Oncimmune Ltd.

Brenig Preest, Non-Executive Director

Mr Preest has over 20 years' experience in the finance and healthcare sectors, primarily as an investor in high growth medical technology and biotechnology opportunities.  He has been involved in over £500m of investments. His early career was at Amersham International (now GE Healthcare) and Coopers & Lybrand (now PwC) and is currently an investment director at Arthurian Life Sciences Limited, a venture capital firm, which provides management services to the Wales Life Sciences Investment Fund LP (being a fund raising up to £100 million focused on life sciences).  He is also a non-executive director at CeQur AG, Apitope BV and SimbecOrion Ltd. Mr Preest is a Chartered Accountant, studied Pharmacology at Cardiff University and financial strategy at the University of Oxford, and was previously elected president for the ICAEW in Wales.